e20659 Background: Immune-related adverse events (irAEs) during immune checkpoint inhibitor (ICI) therapy are associated with improved outcomes in non-small cell lung cancer (NSCLC). However, factors influencing outcomes among patients with irAEs are not well established. This study assesses whether timing of irAEs is associated with outcomes in advanced NSCLC. Methods: This single-center retrospective cohort study included patients with advanced NSCLC treated with ICIs who developed ≥1 irAE. Kaplan–Meier estimates and multivariable Cox models (adjusted for age, sex, ECOG, PD-L1 status, smoking status, and line of therapy) were used to compare PFS and OS between patients with early-onset irAE (≤30 days after ICI start) versus late-onset irAE (>30 days). Immortal time bias was addressed via prespecified landmark analyses at 180 days and a modified 180-day landmark restricted to irAE onset 180-day landmark 90 PFS 13.6 24.6 2.20 (1.06-4.57) 99 OS 18.4 41.7 2.65 (1.36-5.16) > 180-day modified landmark w/ irAE <180 days 52 PFS 13.6 18.3 2.30 (0.98-5.41) 61 OS 18.4 30.9 2.54 (1.24-5.20) ICI discontinuation due to an irAE 64 PFS from ICI stop 2.5 19.2 4.00 (1.82-8.80) 64 OS from ICI stop 4.6 27.8 4.10 (1.75-9.61)
Gorzewski et al. (Thu,) studied this question.